PUBLISHER: DelveInsight | PRODUCT CODE: 1179466
PUBLISHER: DelveInsight | PRODUCT CODE: 1179466
DelveInsight's " Endometriosis - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the endometriosis, historical and forecasted epidemiology as well as the endometriosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The endometriosis market report provides current treatment practices, emerging drugs, endometriosis market share of the individual therapies, current and forecasted endometriosis market size from 2019 to 2032 segmented by seven major markets. The report also covers current endometriosis treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032
The DelveInsight's Endometriosis market report gives a thorough understanding of the disease. Endometriosis is a disease distinguished by endometrial tissue outside the uterine cavity with recurrent intralesional bleeding because of the hormonal responsiveness of ectopic endometrial tissue, resulting in fibrosis. It is a disease of adolescents and reproductive-aged women commonly associated with chronic pelvic pain and infertility. The most common locations for endometriosis are the ovaries, pelvic peritoneum, uterosacral ligaments, and torus uterinus. Atypical pelvic endometriosis localizations can occur in the cervix, vagina, round ligaments, ureter, and nerves. Moreover, rare extrapelvic endometriosis implants can be localized in the upper abdomen, subphrenic fold, or abdominal wall.
The diagnosis of endometriosis has usually delayed an average of 4-11 years from the onset of symptoms due to the non-existence of a pathognomonic test or biomarker to detect the disease but also to the diversity of symptoms that could be considered physiologic responses during menstruation (like pain and discomfort) but also to the wide range of reported symptoms overlap with other gastrointestinal or gynecological causes. To achieve a proper diagnosis of endometriosis, the physician should start by taking a detailed history and performing a gynecological physical examination. The gold standard diagnostic tool remains laparoscopy, combined with an abdominal cavity exploration and a histological biopsy. However, ovarian endometrioma and deep nodular forms of the disease can be detected through ultrasonography and MRI.
Treatment
The management of endometriosis requires a multidisciplinary approach with surgical diagnosis and debulking of disease load, hormonal treatment to suppress and delay recurrence and progression of disease, pain management strategies best provided by a pain center clinic that develops individualized care plans, and pelvic therapy. Symptomatic endometriosis is typically treated by surgical or medical treatment, both equally effective. Despite the available associated pain treatments, endometriosis recurrence is not uncommon. Medical treatment choices are based on side effect profile, cost, and personal preference. Non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose combined oral contraceptive pills (COCPs) such as ethyl estradiol and progestins are the first choice drugs. If patients do not respond to NSAIDs in 3 months, the second line of treatments is used, which includes progestins (oral, injectable, and intra-uterine), androgens, and gonadotropin-releasing hormone agonists (GnRH), which reduce moderate-to-severe pain of endometriosis.
The endometriosis epidemiology division provides insights about historical and current endometriosis patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted endometriosis epidemiology scenario in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.
In 2021, the total prevalent cases of endometriosis were ~ 21,920,000 in the 7MM, which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted endometriosis epidemiology [segmented as Total Prevalent Cases of Endometriosis, Total Diagnosed Prevalent Cases of Endometriosis, Age-specific Diagnosed Prevalent Cases of Endometriosis, Diagnosed Prevalent Cases of Endometriosis by Pain Severity, and Total Treated Cases of Endometriosis] in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.
The epidemiology segment also provides the endometriosis epidemiology data and findings across the United States, EU4 and the UK, and Japan.
The drug chapter segment of the endometriosis report encloses the detailed analysis of endometriosis marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the endometriosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for endometriosis treatment.
Endometriosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted endometriosis market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the endometriosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the endometriosis market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
The Endometriosis market size in the 7MM is expected to change during the study period 2019-2032. The therapeutic market of endometriosis in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of endometriosis was ~USD 1,920 million which is expected to rise during the study period (2019-2032).
The total market size of endometriosis in the United States accounted for ~USD 1,190 million in 2021 which is expected to rise during the study period (2019-2032).
In EU4 and the UK, the total market size of endometriosis was ~USD 590 million in 2021, which is expected to rise during the study period (2019-2032).
In Japan, the total market size of endometriosis was ~USD 130 million in 2021, which is expected to rise during the study period (2019-2032).
Endometriosis Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the endometriosis market or expected to get launched in the market during the study period 2019-2032. The analysis covers endometriosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Endometriosis Development Activities
The report provides insights into different therapeutic candidates in the Phase II, and Phase III stages. It also analyses endometriosis key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for endometriosis emerging therapies.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the endometriosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or endometriosis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitively and Market Intelligence analysis of the Endometriosia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Key Questions
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: